FRISSORA MARK P 4
4 · BIOADAPTIVES, INC. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
BioAdapatives (BDPT) Director Mark Frissora Receives Preferred Stock Award
What Happened Mark P. Frissora, a director of BioAdapatives, Inc. (BDPT), was issued 2,578 shares of Series D Convertible Preferred Stock on 2026-03-01 as compensation for board services. The reported acquisition price is $0.00 (award/grant); the filing classifies the transaction as an "other acquisition" (code J) of a derivative security.
Key Details
- Transaction date: 2026-03-01; Form 4 filed 2026-03-03 (timely filing).
- Security: 2,578 shares of Series D Convertible Preferred Stock issued as board compensation.
- Reported dollar price: $0.00 (compensation award).
- Conversion: Each preferred share converts into 100 shares of common stock — a potential common equivalent of 257,800 shares.
- Conversion limits/conditions: Conversions are subject to a 4.9% beneficial ownership limitation and may not be converted until six months after issuance (except upon liquidation, when conversion occurs immediately). Conversion right does not expire.
- Voting: Each Series D preferred share carries 100 votes at stockholder meetings/consents regardless of the ownership limitation.
- Shares owned after transaction: Not specified in the filing.
Context This was a compensation grant to a director (an acquisition of a derivative security), not an open-market purchase or sale. For retail investors, note this increases the number of outstanding convertible securities and the potential future dilution if converted, but conversion is limited and restricted for six months. The filing shows no sale or cash transaction by the director.
Insider Transaction Report
- Other
Series D Convertible Preferred Stock
[F2][F1]2026-03-01+2,578→ 62,360 totalFrom: 2026-09-01→ Common Stock (257,800 underlying)
Footnotes (2)
- [F1]Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person.
- [F2]The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.